Chembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022
April 21 2022 - 4:05PM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care
diagnostics company focused on infectious diseases, announced today
that it will release financial results for the first quarter of
2022 after the close of trading on Thursday, May 5, 2022.
The company’s management team will host a corresponding
conference call beginning at 4:30 p.m. Eastern Time on May 5, 2022.
Investors interested in listening to the conference call may do so
by dialing 888-506-0062 from the US or 973-528-0011 from outside
the US and providing Entry Code: 898553 or by accessing
www.chembio.com/investors/calendar-of-events/. A replay of the call
will be available by dialing 877-481-4010 from the US or
919-882-2331 from outside the US using passcode 45278 or by
accessing www.chembio.com/investors/calendar-of-events/.
About Chembio DiagnosticsChembio is a leading
diagnostics company focused on developing and commercializing
point-of-care tests used for the rapid detection and diagnosis of
infectious diseases, including sexually transmitted disease, insect
vector and tropical disease, COVID-19 and other viral and bacterial
infections, enabling expedited treatment. Coupled with Chembio’s
extensive scientific expertise, its novel DPP technology offers
broad market applications beyond infectious disease. Chembio’s
products are sold globally, directly and through distributors, to
hospitals and clinics, physician offices, clinical laboratories,
public health organizations, government agencies, and consumers.
Learn more at www.chembio.com.
Investor contact: |
Philip TaylorGilmartin Group(415) 937-5406investor@chembio.com |
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Sep 2023 to Sep 2024